A Phase 1, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Local Muscle Injections of ACE-083 in Healthy Postmenopausal Women
Phase of Trial: Phase I
Latest Information Update: 14 Jan 2020
Price : $35 *
At a glance
- Drugs Efmitermant alfa (Primary)
- Indications Muscular dystrophies
- Focus Adverse reactions; First in man
- Sponsors Acceleron Pharma
- 28 Feb 2018 Final results from this trial published online in the journal Muscle & Nerve, according to an Acceleron Pharma media release.
- 08 Jul 2016 According to an Acceleron Pharma media release, results from this trial were presented at the 14th International Congress on Neuromuscular Disease.
- 08 Jul 2016 Results published in the Acceleron Pharma media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History